Novo Nordisk delays the full US launch of its obesity drug again, as Lilly breathes down its neck.
Real-world data on Translarna look good, but with a failed confirmatory trial and a troubled history US approval is far from guaranteed.
If Jemperli might effectively cure a biomarker-defined subset of rectal cancer patients why isn't pharma more interested?
Another strong readout could redefine how Her2-negative breast cancer is treated, though a declared victory in triple-negatives is less clear.
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?